Cargando…
Case report: lactic acidosis and rhabdomyolysis during telbivudine and tenofovir treatment for chronic hepatitis B
BACKGROUND: Current treatment options for chronic hepatitis B (CHB) are pegylated interferon alpha and nucleoside analogues (NAs). NAs have relatively fewer side effects than interferon alpha, and generally well tolerated. Previously 12.9% of patients on telbivudine treatment were reported to develo...
Autores principales: | Ying, Yue, Hu, Yue-Kai, Jin, Jia-Lin, Zhang, Ji-Ming, Zhang, Wen-Hong, Huang, Yu-Xian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5889588/ https://www.ncbi.nlm.nih.gov/pubmed/29625557 http://dx.doi.org/10.1186/s12876-018-0773-3 |
Ejemplares similares
-
Rhabdomyolysis, lactic acidosis, and multiple organ failure during telbivudine treatment for hepatitis B: a case report and review of the literature
por: Zheng, Jinxin, et al.
Publicado: (2017) -
Role of tenofovir and telbivudine in treatment of hepatitis B related acute on chronic liver failure
por: Malakar, Debraj, et al.
Publicado: (2021) -
Telbivudine vs tenofovir in hepatitis B e antigen-negative chronic hepatitis B patients: OPTIMA roadmap study
por: Krastev, Zahari, et al.
Publicado: (2016) -
Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response
por: Woo, Hyun Young, et al.
Publicado: (2020) -
A randomized open label trial of tenofovir monotherapy versus tenofovir plus telbivudine in spontaneous reactivation of hepatitis B
por: Jindal, Ankur, et al.
Publicado: (2019)